Physician profile
Eric J Schmitt
NPI 1316912900
$7,523.38
in general payments reported to CMS, 2019-2025
29 companies · $625 in 2025
The $625 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,005 · 2020: $835 · 2021: $805 · 2022: $1,595 · 2023: $1,417 · 2024: $1,242 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,209 · Education: $74.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,209.46 |
| Education | $74.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,486.56 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Regeneron Healthcare Solutions, INC. | $1,037.66 | 2019-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $770.84 | 2021-2025 | Orladeyo |
| Glaxosmithkline, LLC. | $645.05 | 2020-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $605.14 | 2020-2025 | Takhzyro, Cuvitru, Eohilia |
| Pharming Healthcare, INC. | $368.71 | 2019-2025 | Ruconest |
| Optinose US, INC. | $356.88 | 2019-2022 | |
| Alk-Abello, INC | $338.70 | 2019-2022 | |
| Genzyme Corporation | $314.96 | 2019-2024 | |
| Pfizer INC. | $241.27 | 2020-2025 | |
| Grifols USA, LLC | $236.52 | 2019-2023 | Xembify |
| Csl Behring | $182.07 | 2019-2024 | Privigen, Hizentra |
| Amgen INC. | $127.28 | 2020-2023 | Tezspire |
| Novartis Pharmaceuticals Corporation | $118.74 | 2023-2024 | |
| Shire North American Group INC | $107.98 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $97.48 | 2020-2021 | |
| Abbvie INC. | $75.20 | 2022 | |
| Biocryst Pharmaceuticals, INC. | $63.14 | 2020-2025 | Orladeyo |
| Mylan Specialty L.P. | $61.09 | 2019-2024 | Yupelri |
| Celgene Corporation | $60.11 | 2019 | |
| Merck Sharp & Dohme LLC | $43.55 | 2021-2023 | |
| Blueprint Medicines Corporation | $39.56 | 2024 | Ayvakit |
| Aytu Biopharma, INC. | $28.36 | 2020-2021 | |
| Lilly USA, LLC | $27.13 | 2025 | Taltz, Ebglyss |
| Genentech USA, INC. | $26.56 | 2023 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $22.10 | 2025 | Neffy |
| Tersera Therapeutics LLC | $14.63 | 2025 | Quzyttir |
| Teva Pharmaceuticals USA, INC. | $14.21 | 2020 | |
| Nabriva Therapeutics, Plc | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Schmitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.